134 related articles for article (PubMed ID: 35001057)
21. Bilateral cystic adrenal neuroblastoma with cystic metastasis in the liver.
Chacko J; Karl S; Sen S; Eapen A; Mathai J
J Pediatr Surg; 2007 Aug; 42(8):E11-3. PubMed ID: 17706480
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
23. [Chromosomal studies in metastatic neuroblastoma].
Franke F; Lampert F
Onkologie; 1982 Dec; 5(6):268-72. PubMed ID: 6762516
[TBL] [Abstract][Full Text] [Related]
24. Features and outcome of neuroblastoma detected before birth.
Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
[TBL] [Abstract][Full Text] [Related]
25. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
26. Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.
Bishop MW; Yin H; Shimada H; Towbin AJ; Miethke A; Weiss B
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e31-5. PubMed ID: 23528904
[TBL] [Abstract][Full Text] [Related]
27. 11q deletion in neuroblastoma: a review of biological and clinical implications.
Mlakar V; Jurkovic Mlakar S; Lopez G; Maris JM; Ansari M; Gumy-Pause F
Mol Cancer; 2017 Jun; 16(1):114. PubMed ID: 28662712
[TBL] [Abstract][Full Text] [Related]
28. Bilateral adrenal neuroblastoma.
Ishiguro Y; Iio K; Seo T; Nagaya M; Ito T
Eur J Pediatr Surg; 1994 Feb; 4(1):37-9. PubMed ID: 8199131
[TBL] [Abstract][Full Text] [Related]
29. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
30. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
31. Stage 4S neuroblastoma, a disseminated tumor with excellent outcome.
Elimam NA; Atra AA; Fayea NY; Al-Asaad TG; Khattab TM; Al-Sulami GA; Felimban SK
Saudi Med J; 2006 Nov; 27(11):1734-6. PubMed ID: 17106552
[TBL] [Abstract][Full Text] [Related]
32. Molecular cytogenetic characterization of two non-MYCN amplified neuroblastoma cell lines with complex t(11;17).
McConville CM; Dyer S; Rees SA; Luttikhuis ME; McMullan DJ; Vickers SJ; Ramani P; Redfern D; Morland BJ
Cancer Genet Cytogenet; 2001 Oct; 130(2):133-40. PubMed ID: 11675134
[TBL] [Abstract][Full Text] [Related]
33. Hemorrhagic shock due to spontaneous rupture of adrenal neuroblastoma in an infant: a rare case and review of the literature.
Honda S; Miyagi H; Minato M; Kubota KC; Okada T
J Pediatr Hematol Oncol; 2012 Nov; 34(8):635-7. PubMed ID: 23018564
[TBL] [Abstract][Full Text] [Related]
34. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
35. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
36. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
Breen CJ; O'Meara A; McDermott M; Mullarkey M; Stallings RL
Cancer Genet Cytogenet; 2000 Jul; 120(1):44-9. PubMed ID: 10913676
[TBL] [Abstract][Full Text] [Related]
37. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
[TBL] [Abstract][Full Text] [Related]
38. Massive hepatomegaly in a 6-week-old infant: is it neuroblastoma?
Okoji GO; Dotollo RA
Ann Trop Paediatr; 1994; 14(4):337-41. PubMed ID: 7880099
[TBL] [Abstract][Full Text] [Related]
39. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
40. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]